

Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P3AD4F89B6B0EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: P3AD4F89B6B0EN

Abstracts

The 7 major pemphigus vulgaris markets reached a value of US\$ 265.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 519.4 Million by 2034, exhibiting a growth rate (CAGR) of 6.3% during 2024-2034.

The pemphigus vulgaris market has been comprehensively analyzed in IMARC's new report titled "Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pemphigus vulgaris is a rare autoimmune disorder that affects the skin and mucous membranes, causing painful blistering and erosions. It can affect in various areas of the body, such as the mouth, throat, nose, genitals, abdomen, etc. The symptoms of the condition typically include the formation of fragile, fluid-filled blisters, leaving open sores that are painful and prone to infection. Various other indications are itching, burning, pain in affected areas, fever, fatigue, weight loss, etc. The ailment is diagnosed through a combination of clinical examination, skin biopsy, and blood tests. The healthcare professionals will typically begin by conducting a physical exam to assess the extent and severity of the blistering and erosions. They may also take a biopsy of the affected skin or mucous membrane to look for characteristic changes in the cells and tissues. Additionally, blood tests may be ordered to detect the presence of antibodies associated with pemphigus vulgaris.

The rising cases of immune system malfunction in which antibodies attack the proteins that hold skin cells together are primarily driving the pemphigus vulgaris market. Additionally, the escalating usage of various medications, such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, penicillamine, etc., which aid in triggering the onset of the ailment, is also propelling the market growth. Besides this, the widespread adoption of immunosuppressive agents in conjunction with

corticosteroids to control the immune system and prevent the formation of new blisters is creating a positive outlook for the market. Moreover, the emerging popularity of plasmapheresis for treating severe cases of disease that do not respond to other treatments is acting as another significant growth-inducing factor. This procedure is used to remove autoantibodies and other immune system components that contribute to the development of the ailment. Furthermore, the rising usage of indirect immunofluorescence for diagnosing the disorder, which involves using fluorescent antibodies to detect the presence of autoantibodies, is also augmenting the market growth. Apart from this, the escalating demand for intravenous immunoglobulin therapy among patients with refractory disease or who are unable to tolerate systemic corticosteroids is expected to drive the pemphigus vulgaris market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pemphigus vulgaris market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pemphigus vulgaris and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pemphigus vulgaris market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the pemphigus vulgaris market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the pemphigus vulgaris market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pemphigus vulgaris marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the pemphigus vulgaris market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the pemphigus vulgaris market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the pemphigus vulgaris market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of pemphigus vulgaris across the seven major markets?

What is the number of prevalent cases (2018-2034) of pemphigus vulgaris by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of pemphigus vulgaris by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with pemphigus vulgaris across the seven major markets?

What is the size of the pemphigus vulgaris patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of pemphigus vulgaris?

What will be the growth rate of patients across the seven major markets?

Pemphigus Vulgaris: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for pemphigus vulgaris drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the pemphigus vulgaris market?

What are the key regulatory events related to the pemphigus vulgaris market?

What is the structure of clinical trial landscape by status related to the pemphigus vulgaris market?

What is the structure of clinical trial landscape by phase related to the pemphigus vulgaris market?

What is the structure of clinical trial landscape by route of administration related to the pemphigus vulgaris market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PEMPHIGUS VULGARIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PEMPHIGUS VULGARIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PEMPHIGUS VULGARIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PEMPHIGUS VULGARIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PEMPHIGUS VULGARIS - UNMET NEEDS

10 PEMPHIGUS VULGARIS - KEY ENDPOINTS OF TREATMENT

11 PEMPHIGUS VULGARIS - MARKETED PRODUCTS

- 11.1 List of Pemphigus Vulgaris Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Rituxan (Rituximab) - Biogen Idec/Genentech
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PEMPHIGUS VULGARIS - PIPELINE DRUGS

12.1 List of Pemphigus Vulgaris Pipeline Drugs Across the Top 7 Markets

12.1.1 PRN1008 - Principia Biopharma

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 DSG3 CAART - Cabaletta Bio

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 PH20 SC - argenx

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 VAY736 - MorphoSys/Novartis

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PEMPHIGUS VULGARIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PEMPHIGUS VULGARIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 PEMPHIGUS VULGARIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Pemphigus Vulgaris - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Pemphigus Vulgaris - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Pemphigus Vulgaris - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Pemphigus Vulgaris - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Pemphigus Vulgaris - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Pemphigus Vulgaris - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Pemphigus Vulgaris - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Pemphigus Vulgaris - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Pemphigus Vulgaris - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Pemphigus Vulgaris - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Pemphigus Vulgaris - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Pemphigus Vulgaris - Market Size

15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Pemphigus Vulgaris - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Pemphigus Vulgaris - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Pemphigus Vulgaris - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Pemphigus Vulgaris - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Pemphigus Vulgaris - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Pemphigus Vulgaris - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Pemphigus Vulgaris - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Pemphigus Vulgaris - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Pemphigus Vulgaris - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Pemphigus Vulgaris - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Pemphigus Vulgaris - Access and Reimbursement Overview

16 PEMPHIGUS VULGARIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PEMPHIGUS VULGARIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PEMPHIGUS VULGARIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Pemphigus Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P3AD4F89B6B0EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P3AD4F89B6B0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

